This allows the prebiotic blends to slowly cultivate butyrate-producing bacteria without overwhelming the system
Additional Phase 3 trials are still underway, including TRIUMPH-2 (evaluating retatrutide in adults with obesity and type 2 diabetes) and TRIUMPH-3 (evaluating cardiovascular outcomes), with results expected later in 2026
For example, this requires you to have two or more medical conditions, such as malignant melanoma and anxiety
In: Ferrari R, Dimauro S, Sherwood G, editors
What factors could limit the widespread adoption of GLP-1 receptor agonists despite their proven benefits in HbA1c reduction, weight loss, and cardiovascular risk management, and how might healthcare systems address these barriers
Firstly, only 10 studies met the inclusion criteria, highlighting the need for additional research across different populations, regions, and ethnicities